These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Window of opportunity for treatment of rheumatoid arthritis].
    Author: Fukuda T.
    Journal: Nihon Rinsho; 2007 Jul; 65(7):1276-81. PubMed ID: 17642243.
    Abstract:
    Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology characterized by symmetric, erosive synovitis. Joints become eroded in the first 2 years of early RA. But the subsequent course of radiological progression is highly variable and cannot be easily explained. Their disability correlates with signs and symptoms of inflammation and it correlates more closely with articular damage. TNF blockers (infliximab and etanercept) affect signs and symptoms as well as radiographic progression of RA. They are among the most effective therapies for RA. Early diagnosis and early appropriate treatment of RA are thought to be key to controlling progress of disease and preventing further joint and tissue damage. The concept of "window of opportunity" exists from the notion that early institution of therapy for RA is more effective in preventing joint damage, decreasing functional disability, and inducing clinical remission.
    [Abstract] [Full Text] [Related] [New Search]